The Clinical Numbers at 18 Months

Wegovy's efficacy data comes primarily from the STEP trial program, one of the most rigorous obesity treatment research efforts ever conducted:

• STEP 1 (68 weeks): 1,961 participants. Average weight loss of 14.9% of body weight on semaglutide 2.4 mg versus 2.4% on placebo. That is roughly 34 pounds from a starting weight of 232 pounds .
• STEP 3 (68 weeks, with intensive behavioral therapy): Average weight loss of 16.0% of body weight, demonstrating that Wegovy plus lifestyle intervention outperforms either approach alone .
• STEP 5 (104 weeks): Sustained weight loss of 15.2% at 2 years, confirming that results hold over longer treatment periods. At the 18-month midpoint, results were consistent with STEP 1 outcomes .

Approximately 86% of participants on Wegovy lost at least 5% of their body weight, and about 32% lost 20% or more, a threshold previously only reached with bariatric surgery .

Month-by-Month Timeline to 18 Months

• Weeks 1 to 4 (0.25 mg): Starting titration dose. Minimal weight loss (1 to 3 lbs). Body adjusting to the medication. Nausea and mild GI effects are common.
• Weeks 5 to 8 (0.5 mg): Appetite suppression becomes noticeable. Cumulative loss of 3 to 6 pounds.
• Weeks 9 to 12 (1.0 mg): Steady loss begins. Cumulative loss of 6 to 12 pounds. Food noise decreases significantly.
• Weeks 13 to 16 (1.7 mg): Approaching full therapeutic dose. Cumulative loss of 10 to 17 pounds. Many patients report a dramatic shift in eating habits.
• Months 5 to 8 (2.4 mg maintenance): Peak weight loss rate. Losing approximately 1 to 2 pounds per week. Cumulative loss of 18 to 30 pounds.
• Months 9 to 12: Continued steady loss but rate begins to slow. Cumulative loss of 28 to 38 pounds.
• Months 13 to 15: Weight loss decelerates further. Cumulative loss of 32 to 40 pounds. Body approaching new equilibrium.
• Months 16 to 18: Most patients reach their plateau. Cumulative loss of 30 to 42+ pounds. The medication now primarily prevents regain.

Cardiovascular Benefits at 18 Months

Wegovy made history as the first obesity medication to demonstrate cardiovascular risk reduction in a dedicated outcomes trial:

• The SELECT trial: 17,604 participants with obesity and established cardiovascular disease. Semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% over a median follow-up of 40 months .
• This cardiovascular benefit was independent of whether patients had diabetes.
• Based on these results, Wegovy received an expanded FDA indication for cardiovascular risk reduction in patients with obesity and heart disease .

At 18 months, patients are well into the window where these protective effects are active, adding significant value beyond weight loss alone.

Side Effect Profile at 18 Months

Long-term tolerability is a key concern, and the data is reassuring for most patients:

• Nausea: Peaks during dose escalation (months 1 to 4). By 18 months, only about 5% to 8% of patients report any ongoing nausea.
• Constipation: Affects about 24% of patients at some point. Manageable with fiber supplementation and hydration for most.
• Diarrhea: Reported by 18% during the trial period, mostly during titration.
• Gallbladder events: Gallstones occurred in about 2.6% of Wegovy patients versus 1.2% on placebo in STEP trials. Risk is higher with faster weight loss .
• Pancreatitis: Very rare (less than 0.2%) but remains a monitored concern .

Overall, the dropout rate due to side effects in STEP trials was approximately 7%, meaning the vast majority of patients tolerate long-term treatment well.

Maximizing Results Through 18 Months

• Pair with structured nutrition: A diet rich in lean protein (30+ grams per meal), fiber, and healthy fats helps maximize results and preserve muscle.
• Incorporate resistance training: Lifting weights or doing bodyweight exercises 2 to 3 times per week is the most effective way to protect lean body mass during extended weight loss.
• Walk daily: 8,000 to 10,000 steps per day supports metabolic health and improves cardiovascular outcomes independently of structured exercise.
• Stay on schedule: Take Wegovy on the same day each week. Use a phone alarm or calendar reminder.
• Get regular labs: Monitor metabolic markers every 3 to 6 months. Track improvements to stay motivated.
• Address mental health: Significant body changes can affect self-image and relationships. Do not hesitate to seek support if needed.

Frequently Asked Questions

Is 18 months the maximum time I should take Wegovy?

No. Wegovy is approved for long-term use, and clinical evidence supports continued treatment beyond 18 months. The STEP 5 trial showed sustained benefit at 2 years, and the SELECT trial followed patients for up to 5 years .

What if I plateau before 18 months on Wegovy?

A plateau before 18 months is not unusual, particularly if it begins around months 10 to 12. Strategies include increasing physical activity, adjusting macronutrient ratios, improving sleep quality, or discussing with your provider whether switching to tirzepatide might restart progress.

How does Wegovy compare to Zepbound at 18 months?

Zepbound (tirzepatide) produces approximately 5% to 7% more total body weight loss than Wegovy at similar timepoints. However, Wegovy has the advantage of proven cardiovascular risk reduction data from the SELECT trial, which Zepbound does not yet have.

Will my insurance keep covering Wegovy for 18 months?

Most insurance plans that cover Wegovy do so on an ongoing basis as long as you continue to meet medical necessity criteria. Some plans require periodic reauthorization. Check with your insurer about their renewal policy $1,300-$1,400/mo (brand).

Can I lower my dose after reaching my goal weight?

Some providers explore dose reduction for patients in stable maintenance. However, the STEP 4 trial showed that reducing or stopping semaglutide led to weight regain . Any changes should be gradual and medically supervised.

Continue Your Wegovy Journey with Confidence

Reaching 18 months on Wegovy puts you in a strong position for long-term health improvement. To make the most of your progress and plan wisely for what comes next, work with a provider who specializes in GLP-1 therapy. FormBlends offers ongoing clinical support tailored to your stage of treatment.

Book a follow-up consultation to optimize your Wegovy treatment plan.